Efficacy and safety of fosaprepitant for the prevention of nausea and emesis during 5 weeks of chemoradiotherapy for cervical cancer (the GAND-emesis study): a multinational, randomised, placebo-controlled, double-blind, phase 3 trial
Titel:
Efficacy and safety of fosaprepitant for the prevention of nausea and emesis during 5 weeks of chemoradiotherapy for cervical cancer (the GAND-emesis study): a multinational, randomised, placebo-controlled, double-blind, phase 3 trial
Auteur:
Ruhlmann, Christina H Christensen, Thomas Broe Dohn, Line Hammer Paludan, Merete Rønnengart, Eva Halekoh, Ulrich Hilpert, Felix Feyer, Petra Kristensen, Gunnar Hansen, Olfred Keefe, Dorothy Herrstedt, Jørn